Literature DB >> 2843451

Affinities and densities of high-affinity [3H]muscimol (GABA-A) binding sites and of central benzodiazepine receptors are unchanged in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy.

R F Butterworth1, J Lavoie, J F Giguère, G Pomier-Layrargues.   

Abstract

The integrity of GABA-A receptors and of central benzodiazepine receptors was evaluated in membrane preparations from prefrontal cortex and caudate nuclei obtained at autopsy from nine cirrhotic patients who died in hepatic coma and an equal number of age-matched control subjects. Histopathological studies revealed Alzheimer Type II astrocytosis in all cases in the cirrhotic group; controls were free from neurological, psychiatric or hepatic diseases. Binding to GABA-A receptors was studied using [3H]muscimol as radioligand. The integrity of central benzodiazepine receptors was evaluated using [3H]flunitrazepam and [3H]Ro15-1788. Data from saturation binding assays was analyzed by Scatchard plot. No modifications of either affinities (Kd) or densities (Bmax) of [3H]muscimol of central benzodiazepine binding sites were observed. These findings do not support recent suggestions that alterations of either high-affinity GABA or benzodiazepine receptors play a significant role in the pathogenesis of hepatic encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843451     DOI: 10.1002/hep.1840080517

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  19 in total

Review 1.  Positron emission tomography in the study of hepatic encephalopathy.

Authors:  Alan H Lockwood
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

Review 2.  Pathogenesis and treatment of portal-systemic encephalopathy: an update.

Authors:  R F Butterworth
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

Review 3.  Neurochemistry of hepatic encephalopathy.

Authors:  C O Record
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

4.  Cerebrospinal fluid amino acids in relation to neurological status in experimental portal-systemic encephalopathy.

Authors:  G Therrien; R F Butterworth
Journal:  Metab Brain Dis       Date:  1991-06       Impact factor: 3.584

Review 5.  Neuronal cell death in hepatic encephalopathy.

Authors:  Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

Review 6.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

7.  Electrically evoked synaptosomal amino acid transmitter release in human brain in alcohol misuse.

Authors:  Sheng-Wen Kuo; Peter R Dodd
Journal:  Neurosignals       Date:  2011-08-11

8.  Benzodiazepine binding sites in alcoholic cirrhotics: evidence for gender differences.

Authors:  P R Dodd
Journal:  Metab Brain Dis       Date:  1995-03       Impact factor: 3.584

Review 9.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

Review 10.  The neurosteroid system: an emerging therapeutic target for hepatic encephalopathy.

Authors:  Samir Ahboucha; Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.